Resources from the same session
R&D for radioligand therapies in oncology (preclinical): Target discovery, spatial target expression and tumour microenvironment
Presenter: Bart Cornelissen
Session: ESMO Colloquium supported by Novartis - Radiotheranostics in oncology: Optimising the science, building capacity and streamlining the regulation
Resources:
Slides
Webcast
Clinical drug development of radiotheranostics: Trial design, administered vs absorbed dose and the role of internal dosimetry
Presenter: Alessandra Gennari
Session: ESMO Colloquium supported by Novartis - Radiotheranostics in oncology: Optimising the science, building capacity and streamlining the regulation
Resources:
Slides
Webcast
Current policy and regulatory hurdles for RLT implementation: Regulatory approval, centre accreditation and radioprotection, reimbursement
Presenter: Valentina Di Iorio
Session: ESMO Colloquium supported by Novartis - Radiotheranostics in oncology: Optimising the science, building capacity and streamlining the regulation
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO Colloquium supported by Novartis - Radiotheranostics in oncology: Optimising the science, building capacity and streamlining the regulation
Resources:
Webcast
Concluding remarks
Presenter: Bart Cornelissen
Session: ESMO Colloquium supported by Novartis - Radiotheranostics in oncology: Optimising the science, building capacity and streamlining the regulation
Resources:
Slides
Webcast